Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections - Trial NCT05217537
Access comprehensive clinical trial information for NCT05217537 through Pure Global AI's free database. This Phase 1 trial is sponsored by Paratek Pharmaceuticals Inc and is currently Recruiting. The study focuses on Bacterial Infections. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Paratek Pharmaceuticals Inc
Timeline & Enrollment
Phase 1
Apr 06, 2022
Nov 01, 2023
Primary Outcome
Characterize the PK of a single IV dose of omadacycline in children and adolescents 8 to 18 years of age with suspected or confirmed bacterial infections,Characterize the PK of a single PO dose of omadacycline in children and adolescents 8 to 18 years of age with suspected or confirmed bacterial infections
Summary
The purpose of this study is to evaluate the pharmacokinetics of a single dose of intravenous
 or oral omadacycline in children and adolescents with suspected or confirmed bacterial
 infections.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05217537
Non-Device Trial